Hodgkin lymphoma, nodular lymphocyte predominant (high-power view) Credit: Gabriel Caponetti, MD./Wikipedia/CC BY-SA 3.0 The University of Pennsylvania plans to continue offering CAR-T therapy, a cancer treatment pioneered at Penn, after the Food and Drug...
A day after the FDA launched an investigation into rare cases of secondary blood cancer in patients who received CAR-T therapies, clinicians are calling it a small risk factor for an otherwise effective drug class. Regulators are tracking 20 reports of T-cell...
The FDA is investigating reports of new cancer developments in patients treated with CAR-T cell immunotherapies, specifically targeting BCMA or CD19. This probe, announced on a recent Tuesday, follows cases from clinical trials and postmarketing surveillance where...
The FDA has postponed its decision on approving Bristol Myers Squibb and 2seventy bio’s CAR-T cell therapy for multiple myeloma in earlier treatment lines. Originally expected by December 16, the decision’s delay is due to the FDA’s plan to convene a...
Scope of existing collaboration to include lymphomas and Kite exercises option to Arcellx’s ARC-SparX program ACLX-001 in multiple myeloma. Arcellx, Inc. and Kite, a Gilead Company, have expanded the scope of their existing collaboration for CART-ddBCMA to...
